U.S. flag

An official website of the United States government

Here’s how you know
Here’s how you know

**Official websites use .gov**
A **.gov** website belongs to an official government organization in the United States.

**Secure .gov websites use HTTPS**
A **lock** ( A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Search Query:
			MAIN MENU

																				
              Health Topics
								All Health Topics A-Z
					
													
		

		Asthma


				

															Heart-Healthy Living


				

															High Blood Pressure


				

															Sickle Cell Disease


				

															Sleep Apnea


				

															Information & Resources on COVID-19
																				
              Health Education
								Education Programs and Initiatives
					
													
		

		The Heart Truth®


				

															Learn More Breathe Better®


				

															Blood Diseases and Disorders Education Program


				

															Publications and Resources
																				
              The Science
								Research Focus Areas
					
													
		

		Blood Disorders and Blood Safety


				

															Sleep Science and Sleep Disorders


				

															Lung Diseases


				

															Health Disparities and Inequities


				

															Heart and Vascular Diseases


				

															Precision Medicine Activities


				

															Obesity, Nutrition, and Physical Activity


				

															Population and Epidemiology Studies


				

															Women’s Health


				

															Research Topics


				

															Clinical Trials


				

															All Science A-Z
																				
              Grants and Training
								Grants and Training Home


				

															Policies and Guidelines


				

															Funding Opportunities and Contacts


				

															Training and Career Development
																				
              News and Events
								News and Events Home
					
													
		

		Email Alerts


				

															All News
					
													
		

		NHLBI News


				

															NHLBI in the Press


				

															Research Features


				

															All Events
					
													
		

		Past Events


				

															Upcoming Events
																				
              About NHLBI
								About NHLBI Home
					
													
		

		Mission and Strategic Vision


				

															Leadership


				

															Divisions, Offices and Centers


				

															Advisory Committees


				

															Budget and Legislative Information


				

															Jobs and Working at the NHLBI


				

															Contact and FAQs


				

															NIH Sleep Research Plan
						
						HOME
		Search Text: Home/Grants and Training/< Back ToPolicies, Procedures, and Guidelines/NHLBI Adverse Event and Unanticipated Problem Reporting Policy

NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    
        

    
                1.0 Purpose
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    The purpose is to describe the National Heart, Lung, and Blood Institute (NHLBI) extramural programs’ policy and procedures for adverse event (AE) and unanticipated problem (UP) reporting.


          
    2.0 Scope
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    This policy applies to all human subjects research funded in whole or in part by NHLBI extramural programs.


          
    3.0 Definitions
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    **Adverse event (AE):** OHRP guidance defines AEs as any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research (modified from the definition of adverse events in the 1996 International Conference on Harmonization E-6 Guidelines for Good Clinical Practice).  Adverse events encompass both physical and psychological harms.  They occur most commonly in the context of biomedical research, although on occasion, they can occur in the context of social and behavioral research.

**Serious adverse event (SAE):**OHRP guidance defines SAEs as any adverse event temporally associated with the subject’s participation in research that meets any of the following criteria:

Results in death;
	Is life-threatening (places the subject at immediate risk of death from the event as it occurred);
	Requires inpatient hospitalization or prolongation of existing hospitalization;
	Results in a persistent or significant disability/incapacity;
	Results in a congenital anomaly/birth defect; or
	Any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject’s health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition (examples of such events include allergic bronchospasm requiring intensive treatment in the emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse).(Modified from the definition of serious adverse drug experience in FDA regulations at 21 CFR 312.32(a).)

**Unanticipated Problem (UP):** OHRP guidance defines UPs as any incident, experience, or outcome that meets all of the following criteria:

Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied;
	Related or possibly related to participation in the research (in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and
	Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.


          
    4.0 Policy and Procedures
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    **4.1 Policy**

All human subjects research supported by NHLBI must include procedures for identifying, monitoring, and reporting all AEs, including both serious (SAE) and non-serious events, and UPs. All NHLBI human subjects research will follow a uniform policy, which is based on the FDA/Office for Human Research Protections (OHRP) regulations and guidance including definitions and timelines, as outlined in Sections 4.2 and 4.3.

**4.2 Reporting Procedures and Requirements**

Procedures for identifying, monitoring, and reporting AEs and UPs must be described in the study's Institutional Review Board (IRB)-approved data and safety monitoring (DSM) plan that is submitted to the NHLBI (see NHLBI Data and Safety Monitoring Policy). AE and UP reporting should include at a minimum:

Expedited reporting of serious and unexpected, suspected adverse reactions to the NHLBI based on the definitions and timelines in FDA regulations and/or OHRP guidance. For multi-center studies, this includes procedures for notifying all participating IRBs through the local investigator.
	For all AEs and UPs, individual and summary reporting to local IRBs on a schedule consistent with IRB-written procedures and consistent with FDA/OHRP regulations and guidance.A monitoring person or body, such as a Data and Safety Monitoring Board (DSMB), may require additional expedited reporting. The program official will confirm with the principal investigator that any UP has been reported to the appropriate IRBs and that all corrective action/preventative action plans have been adequately implemented.

**4.3 Reporting Timelines and Guidance**

Refer to the table below for SAE and UP safety reporting requirements and timelines for clinical research funded in whole or in part by NHLBI extramural programs.
	Note that in some cases, more than one set of regulations/guidance may apply to a specific event. For example, in a study with FDA-regulated products, an UP that is also an SAE would require compliance with both FDA regulations and OHRP guidance.
		Reporting timelines for all non-serious AEs should follow the IRB-approved Data and Safety Monitoring Plan for the study.**SAE and UP Event Reporting Timelines**

**What Event is Reported**
			**When is Event Reported**
			**By Whom is Event Reported**
			**To Whom is Event Reported**Fatal or life-threatening unexpected, suspected serious adverse reactions
			Within **7 calendar days** of initial receipt of information
			Investigator
			Local/internal IRBs
				NHLBI and/or Data Coordinating Center (DCC)Sponsor or designee1
			FDA (if IND study)Non-fatal, non-life-threatening unexpected, suspected serious adverse reactions
			Within **15 calendar days** of initial receipt of information
			Investigator
			Local/internal IRBs/Institutional Officials
				NHLBI and/or DCCSponsor or designee
			FDA (IND/Marketed Products)
				All participating investigatorsUnanticipated adverse device effects
			Within **10** working days of investigator first learning of effect
			Investigator
			Local/internal IRBs
				NHLBI and/or DCCSponsor or designee
			FDA (if IDE study)Unanticipated Problem that is not an SAE
			Within **14 days** of the investigator becoming aware of the problem
			Investigator
			Local/internal IRBs/Institutional Officials,
				NHLBI and/or DCCAll Unanticipated Problems2
			Within **30 days** of the IRB’s receipt of the report of the UP from the investigator.
			IRB
			OHRPInvestigator3
			External IRBs1. The Food and Drug Administration (FDA) regulations define the sponsor of a clinical trial (21 CFR 50.3) as the person or entity who initiated the trial. NIH guidance elaborates on the definition and provides examples. Designee is appointed by the sponsor; for example, DCC, CRO.
2. Per OHRP guidance: only when a particular AE or series of AEs is determined to meet the criteria for an UP should a report of the AE(s) be submitted to the IRB at each institution under the HHS regulations at 45 CFR part 46. Typically, such reports to the IRBs are submitted by investigators.
3. Investigators should also take into account local IRB guidance if reporting timelines for UPs are shorter than OHRP guidance


          
    5.0 References
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events, 2007
	HHS regulations for the protection of human subjects (45 CFR part 46)
	FDA Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans
	FDA Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies
	21 CFR 312.32 IND Safety Reporting
	21 CFR 312.64 Investigator Reports
	21 CFR 314.80 Postmarketing Reporting of Adverse Drug Experiences
	New FDA Regulation to Improve Safety Reporting in Clinical Trials (NEJM 2011; 365(1):3-5)
	NHLBI Data and Safety Monitoring Policy, 2011
	NIH Guidance on Reporting Adverse Events to Institutional Review Boards for NIH-Supported Multicenter Clinical Trials, 6/11/1999
	FDA Investigational Device Exemptions
	21 CFR 812 Investigational Device Exemptions (see 812.46(b), 812.150)
	21 CFR 50 Protection of Human Subjects
	21 CFR 50.3 Protection of Human Subjects Definitions
	21 CFR 56 Institutional Review Boards
	21 CFR 56.108 Institutional Review Boards (Unanticipated Problem Reporting)
	Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs- Improving Human Subject Protection.
	Draft Guidance: Elaboration of Definitions of Responsible Party and Applicable Clinical Trial


          
    Revision Record
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    **Revisions/Preceding Policies**
			**Date**Definitions section updated to reflect the Office of Human Research Protections (OHRP) definitions and include additional links to resources
			February 2022Adverse Event Tracking in NHLBI-Supported Clinical Research Studies
			April 2004Policy for Reporting Clinical Study Serious Adverse Events
			May 2002


          
    Contacts
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    For additional information contact the NHLBI Program or Program Official associated with your study. Questions and comments regarding this policy may be directed to Office of Clinical Research, NHLBI.


          
    FAQs
      
	-
		NHLBI Adverse Event and Unanticipated Problem Reporting Policy
    **1. Q: Does this NHLBI policy only apply to clinical trials?****A:**This policy applies to all human subjects research funded in whole or in part by NHLBI extramural programs.**2. Q: What is the difference between an adverse event and an unanticipated problem?
A:**The key question regarding a particular adverse event is whether it meets the three criteria described below and therefore represents an unanticipated problem.  To determine whether an adverse event is an unanticipated problem, the following questions should be asked:

Is the adverse event unexpected?
	Is the adverse event related or possibly related to participation in the research?
	Does the adverse event suggest that the research places subjects or others at a greater risk of harm than was previously known or recognized?
	If the answer to all three questions is yes, then the adverse event is an unanticipated problem.**3. Q: What is the difference between an adverse event and a suspected adverse reaction?****A:**A suspected adverse reaction is any adverse event for which there is a reasonable possibility that study participation caused the adverse event (21 CFR 312.32).**4. Q:  Is this policy for all trials or just FDA-regulated trials?****A:** All NHLBI human subjects research will follow this uniform policy, which is based on the FDA/Office for Human Research Protections (OHRP) regulations and guidance including definitions and timelines, as outlined in Sections 4.2 and 4.3 of the policy.**5. Q: How should non-serious adverse events be reported?****A:**Reporting timelines for all non-serious AEs should follow the IRB-approved Data and Safety Monitoring Plan for the study.**6. Q: What regulations should be followed to report an SAE that is also a UP?****A:**In some cases, more than one set of regulations/guidance may apply to a specific event. For example, in a study with FDA-regulated products, an unexpected problem that is also an SAE would require compliance with both FDA regulations (21 CFR 312.32) and OHRP guidance for a UP.**7. Q: Who makes the final determination of “relatedness?”
A:** The sponsor makes the final determination of AE relatedness to a drug. Under the new regulation (21 CFR 312.32), PIs are now required to report all serious adverse events to the sponsor, whether or not they are considered drug-related.  But it’s difficult for an investigator to attribute a serious adverse event to a drug on the basis of an isolated incident, and individual investigators may not have timely access to the entire safety database. Therefore, causality of adverse events is best evaluated in the aggregate by the sponsor. Back To Top Link
  

        

        Back to top
  Web Policies & Notices
  

        

              Accessibility
                      No FEAR Act Data
                      Privacy Policy
                      Freedom of Information Act (FOIA)
                      HHS Vulnerability Disclosure
    
          Related Government Websites
  

        

              Health and Human Services
                      National Institutes of Health
                      Office of the Inspector General
                      USA.gov
    
          Stay Connected
    
      
            chat bubblesLive ChatLive Chat with us, Monday through Friday, 8:30 a.m. to 5:00 p.m. EST.envelopeGet Email AlertsReceive automatic alerts about NHLBI related news and highlights from across the Institute.
  Footer Bottom
  

        



Contact Us
                            Site Index
                            Jobs